Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A cost‐effectiveness analysis of cell free DNA as a replacement for serum screening for Down syndrome

2 Oct 2014

Abstract excerpt

OBJECTIVE: The aim of this article is to determine the cost effectiveness of cell free DNA (cfDNA) as a replacement for integrated screening using a societal cost perspective. METHOD: This study used Monte-Carlo simulation with one-way and probabilistic sensitivity analysis. RESULTS: Cell free DNA is more effective and less costly than integrated screening. The incremental cost-effectiveness ratio for cfDNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Ethics in Clinical Research
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25273838
DOI: 10.1002/pd.4511

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

A cost‐effectiveness analysis of cell free DNA as a replacement for serum screening for Down syndromePMID 25273838Read ↗

An Economic Analysis of Cell-Free DNA Non-Invasive Prenatal Testing in the US General Pregnancy PopulationSemantic proximity Read ↗

Rapid testing versus karyotyping in Down's syndrome screening: cost-effectiveness and detection of clinically significant chromosome abnormalitiesSemantic proximity Read ↗

The price of performance: a cost and performance analysis of the implementation of cell‐free fetal DNA testing for Down syndrome in Ontario, CanadaSemantic proximity Read ↗

The price of abandoning diagnostic testing for cell‐free fetal DNA screeningSemantic proximity Read ↗

Incorporating DNA Sequencing into Current Prenatal Screening Practice for Down's SyndromeSemantic proximity Read ↗

Cell‐free fetal <scp>DNA</scp> screening in the USA: a cost analysis of screening strategiesSemantic proximity Read ↗

Nuchal translucency and first trimester biochemical markers for down syndrome screening: A cost-effectiveness analysisSemantic proximity Read ↗

First-Trimester down syndrome screening using dried blood biochemistry and nuchal translucencySemantic proximity Read ↗

Estimates for the sensitivity and false-positive rates for second trimester serum screening for Down syndrome and trisomy 18 with adjustment for cross-identification and double-positive resultsSemantic proximity Read ↗

Rapid prenatal diagnostic testing for Down syndrome only or longer wait for full karyotype: the views of pregnant womenSemantic proximity Read ↗

The impact of crown–rump length measurement error on combined Down syndrome screening: a simulation studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.